BloodCancer BiologyPeer-reviewed journal article
Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B Cell Lymphoma
Camiel GöbeliD, Rachele NiccolaiiD, Marnix H. P. de GrootiD, Jayashree JayachandraniD, Joleen J.H. TraetsiD, Daan J. KloostermaniD, Sebastian GregoricchioiD, Ben MorrisiD, Maaike KreftiD, Ji‐Ying SongiD, Leyla AzarangiD, Eirini Kasa, Nienke OskamiD, Daniël de Groot, Liesbeth HoekmaniD, Onno B. BleijerveldiD, Marie José KersteniD, Muhammad Assad AslamiD, Fred van LeeuweniD, Heinz JacobsiD
Abstract
Differentiation of antigen-activated B cells into pro-proliferative germinal center (GC) B cells depends on the activity of the transcription factor MYC and the epigenetic writers DOT1L and EZH2. GCB-like Diffuse Large B Cell Lymphomas (GCB-DLBCLs) arise from GC B cells and closely resemble their cell of origin. Given the dependency of GC B cells on DOT1L and EZH2, we investigated the role of these epigenetic regulators in GCB-DLBCL cell lines and observed that GCB-DLBCLs synergistically depend on the combined activity of DOT1L and EZH2. Mechanistically, inhibiting both enzymes led to enhanced derepression of PRC2 target genes compared to EZH2 single treatment, along with the suppression of MYC target genes. The sum of all these alterations results in a cell-identity crisis, wherein GCB-DLBCLs lose their pro-proliferative GC identity and partially undergo plasma cell differentiation, a state associated with poor survival. In support of this model, combined epi-drugging of DOT1L and EZH2 prohibited the outgrowth of human GCB-DLBCL xenografts in vivo. We conclude that the malignant behavior of GCB-DLBCLs strictly depends on DOT1L and EZH2 and that combined targeting of both epigenetic writers may provide an alternative differentiation-based treatment modality for GCB-DLBCL. Key pointsO_LIMYC-driven GCB-DLBCL depends on DOT1L and EZH2 and combined targeting provides an alternative differentiation-based therapy. C_LIO_LIDOT1L and EZH2 cooperatively repress PRC2 target genes which is essential for acquiring a plasma cell-like state in GC B cell-like DLBCL. C_LI
- organism: human
- assay: ChIP-seq
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
- approach: statistical model
- Citations
- 18
- FWCI
- 15.37
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma
Calixte Calaud, Emilio M. Serrano-López, … Pilar M. Domínguez·Blood NeoplasiaPeer-reviewed·Mar 2, 2026
- EZH2 inhibition results in genome-wide PRC2 redistribution
Chih-Chi Yuan, Ah‐Jung Jeon, … Patrick Trojer·bioRxiv·Dec 29, 2019
- Histone methyltransferase DOT1L controls state-specific identity during B cell differentiation
M. A. Aslam, M. F. Alemdehy, … F. van Leeuwen·bioRxiv·Mar 25, 2020
- Unmasking the cryptic immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas through combination drug treatment
C. M. Bourne, S. S. Mun, … D. A. Scheinberg·bioRxiv·Sep 1, 2021
- BCL10 Gain-of-Function Impairs Germinal Center Participation by Naive B Cells and Cooperates with BCL6 to Drive Extrafollicular Diffuse Large B-Cell Lymphoma
Dhanvantri Chahar, Abdessamad Alaoui Youssfi, … Jonathan H Schatz·bioRxiv·Nov 5, 2026
- Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma
A. R. Iyer, A. Gurumurthy, … R. J. Ryan·bioRxiv·May 2, 2023